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Fig. 2. Immunohistochemical staining (brown) of a number of HHV-6 proteins.
A) Early antigen (E A) p41 staining in the cytoplasm of hepatocytes and Kupffer cells (20X). Inset shows positively staining bodies in the cytoplasm of hepatocytes
(60X) [bar ¼ 100 mM]. B) EA p41 staining of control liver specimen with hemosiderosis showing light background staining in hepatocytes but not in Kupffer cells. C)
Viral capsid antigen (VCA) p140 staining in Kupffer cell cytoplasm, and in a punctate distribution in hepatocyte cytoplasm, both with a patchy distribution. D) VCA
stained control with hemosiderosis showing minimal background staining. E) Envelope glycoprotein (EG) gH stains similarly to VCA with an identical patchy dis-
tribution. F) CD68 staining of the subject liver demonstrating Kupffer cells.
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patient. It is reasonable to consider treating HHV-6 in the
setting of reactivation and hepatitis while diagnostic workup
is underway.353
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Background: Human herpesvirus 6 (HHV-6) reactivates in
33-48% of hematopoietic stem cell transplant (HCT) re-
cipients and is associated with numerous adverse effects.HHV-6 chronically infects cells after primary infection and
has a unique ability to integrate into chromosomal telo-
meres. If this occurs in germ cell lines, vertical transmission
results in individuals with chromosomally integrated HHV-6
(ciHHV-6) in every nucleated cell. Studies have found ciHHV-
6 in an average of 0.85% of blood donors and 1.99% of patient
groups (Rev. Med. Virol. 2012; 22: 144e155). A few reports
suggest that patients with ciHHV-6 can develop in vitro and
in vivo HHV-6 replication and disease. The prevalence of
ciHHV-6 in patients with HHV-6-associated diseases is un-
known and may provide insight into the risk for pathologic
HHV-6 reactivation.
Methods: To determine the prevalence of ciHHV-6 in pa-
tients with HHV-6 end-organ disease, we identiﬁed cases of
HHV-6-associated post-stem cell transplant acute limbic
encephalitis (HHV-6-PALE) and tested patients and their
donors for ciHHV-6. HHV-6-PALE was diagnosed in patients
with HHV-6 DNA in cerebrospinal ﬂuid (CSF) and neurologic
symptoms with no other explanatory etiology. CiHHV-6 was
identiﬁed in blood samples by testing extracted DNA for
HHV-6 and a reference gene for cell count with droplet
digital PCR. Positive samples had a ratio of 1  0.07 HHV-6/
genome equivalents.
Figure. Specimen testing for ciHHV-6
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our institution from 1998-2012, 37 (0.95%) met criteria for
HHV-6-PALE. This cohort had 16 double cord blood, 13 pe-
ripheral blood (PBSCT), and 8 bone marrow HCTs. Median
maximum CSF HHV-6 viral load (VL) was 10,000 copies/ml
(range, 54-450,000). Twenty-six cellular and 11 serum pre-
HCT patient samples were tested for ciHHV-6 (Figure).
CiHHV-6 was detected in 1 of 37 samples (2.7%; 95% CI, 0.07-
14.5%). This patient developed HHV-6-PALE D+12 after PBSCT
with maximum CSF VL of 250,000 copies/ml and died on
D+40 from complications of autopsy-conﬁrmed encephalitis.
Nineteen donor samples (17 cellular, 2 serum) tested nega-
tive for ciHHV-6. Late post-engraftment serum samples were
tested in cases without available donor samples; 4 of 15 had
HHV-6 DNA detected but were indeterminate for ciHHV-6
(Figure).
Conclusions: This is the ﬁrst epidemiologic study of the
prevalence of ciHHV-6 in patients with HHV-6 PALE and
included the largest reported cohort of HHV-6-PALE cases to
date. CiHHV-6 was identiﬁed in one patient, which has never
been described in this setting. Sequencing of pre and post-
HCT viruses, as well as histopathologic testing of brain tissue,
is in process. Although there is no clear evidence of ciHHV-6
enrichment in this cohort, the detection and poor outcome
in the described case underscores the need for a large,
multi-center study to determine the impact of ciHHV-6 on
outcomes.354
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Medical College of Wisconsin, Milwaukee, WINMA doses of FluTBI result in successful donor chimerism
and have the objective of controlling disease through a graft-
versus-tumor effect. Other regimens without irradiation
were developed, mainly for treatment of lymphoma, yet
comparisons of HCT outcomes remain scant. We compared
382 FluTBI recipients to 515 Flu recipients prior to HCT from
2001 to 2011 and reported to the Center for International
Blood and Marrow Transplant Research (CIBMTR). Patients
were 40 years or older with lymphoma and received
matched sibling, HLA matched at 8/8 or 7/8 unrelated donor
(URD) bone marrow (BM) or peripheral blood (PBSC) grafts.
FluTBI cohort had a higher number of patients with Kar-
nofsky performance score (KPS) <90% (32% vs. 22%), more
chronic lymphocytic leukemia (41% vs. 33%), more URD (68%
vs. 51%), more PBSC (94% vs. 85%), less anti-thymocyte
globulin use (11% vs. 15%), less rituximab in the conditioning
(7% vs. 40%), and more mycophenolate mofetil-based graft
vs. host disease prophylaxis (GVHD, 87% vs.15%) compared to
Flu. Impact on hematopoiesis differed according to the
regimen with 24% and 43% of patients never dropping the
absolute neutrophil count <500/mL and platelets <50,000/
mL, respectively, with FluTBI comparing to 2% and 24% with
Flu. Cumulative incidences at 100 days of grades II-IV and III-
IV acute GVHD were 22% and 15% with FluTBI; and 17%
(p¼0.04) and 10% (p¼0.02) for Flu, respectively. Corre-
sponding rates of chronic GVHD at 1 year were 54% and 44%
(p¼0.004). Cumulative incidences at 3 years of transplant
related mortality were 28% and 23% (p¼0.13), and of pro-
gression were 36% and 34% (p¼0.63) for FluTBI and Flu
respectively. Multivariate analysis of TRM, progression,
treatment failure and mortality showed no difference in
outcomes according to the conditioning regimen. Variables
associated with higher mortality were age 50-59y (Hazard
Ratio [HR] 1.31, p¼0.03) and 60y (HR 1.66, p<0.001)
compared to 40-49y; KPS <90% (HR 1.49, p<0.001); and
recipients of 8/8 matched URD (HR 1.28, p¼0.02) and 7/8
matched URD (HR 1.94, p<0.001) compared to sibling donor
HCT. The three-year probabilities of progression free survival
were 40% and 41% (p¼0.81), and overall survival were 50%
and 55% (p¼0.14) after adjusting for factors from the
